310 related articles for article (PubMed ID: 26747009)
1. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
2. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
3. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease.
Assíria Fontes Martins T; de Figueiredo Diniz L; Mazzeti AL; da Silva do Nascimento ÁF; Caldas S; Caldas IS; de Andrade IM; Ribeiro I; Bahia MT
PLoS One; 2015; 10(6):e0128707. PubMed ID: 26076455
[TBL] [Abstract][Full Text] [Related]
4. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
[TBL] [Abstract][Full Text] [Related]
5. Experimental and Clinical Treatment of Chagas Disease: A Review.
Sales Junior PA; Molina I; Fonseca Murta SM; Sánchez-Montalvá A; Salvador F; Corrêa-Oliveira R; Carneiro CM
Am J Trop Med Hyg; 2017 Nov; 97(5):1289-1303. PubMed ID: 29016289
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.
Valdez RH; Tonin LT; Ueda-Nakamura T; Silva SO; Dias Filho BP; Kaneshima EN; Yamada-Ogatta SF; Yamauchi LM; Sarragiotto MH; Nakamura CV
Antimicrob Agents Chemother; 2012 Jan; 56(1):507-12. PubMed ID: 22037851
[TBL] [Abstract][Full Text] [Related]
7. Tackling the challenges of human Chagas disease: A comprehensive review of treatment strategies in the chronic phase and emerging therapeutic approaches.
Ramos LG; de Souza KR; Júnior PAS; Câmara CC; Castelo-Branco FS; Boechat N; Carvalho SA
Acta Trop; 2024 Aug; 256():107264. PubMed ID: 38806090
[TBL] [Abstract][Full Text] [Related]
8. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
Wilkinson SR; Taylor MC; Horn D; Kelly JM; Cheeseman I
Proc Natl Acad Sci U S A; 2008 Apr; 105(13):5022-7. PubMed ID: 18367671
[TBL] [Abstract][Full Text] [Related]
9. New drug discovery strategies for the treatment of benznidazole-resistance in
Murta SMF; Lemos Santana PA; Jacques Dit Lapierre TJW; Penteado AB; El Hajje M; Navarro Vinha TC; Liarte DB; de Souza ML; Goulart Trossini GH; de Oliveira Rezende Júnior C; de Oliveira RB; Ferreira RS
Expert Opin Drug Discov; 2024 Jun; 19(6):741-753. PubMed ID: 38715393
[TBL] [Abstract][Full Text] [Related]
10. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.
Forsyth CJ; Hernandez S; Olmedo W; Abuhamidah A; Traina MI; Sanchez DR; Soverow J; Meymandi SK
Clin Infect Dis; 2016 Oct; 63(8):1056-1062. PubMed ID: 27432838
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression and Chagas disease: a management challenge.
Pinazo MJ; Espinosa G; Cortes-Lletget C; Posada Ede J; Aldasoro E; Oliveira I; Muñoz J; Gállego M; Gascon J
PLoS Negl Trop Dis; 2013; 7(1):e1965. PubMed ID: 23349998
[TBL] [Abstract][Full Text] [Related]
12. Chagas disease: hidden affliction and visible neglect.
Weir E
CMAJ; 2006 Apr; 174(8):1096. PubMed ID: 16606958
[No Abstract] [Full Text] [Related]
13. Towards a paradigm shift in the treatment of chronic Chagas disease.
Viotti R; Alarcón de Noya B; Araujo-Jorge T; Grijalva MJ; Guhl F; López MC; Ramsey JM; Ribeiro I; Schijman AG; Sosa-Estani S; Torrico F; Gascon J;
Antimicrob Agents Chemother; 2014; 58(2):635-9. PubMed ID: 24247135
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity.
Zingales B; Miles MA; Moraes CB; Luquetti A; Guhl F; Schijman AG; Ribeiro I; ;
Mem Inst Oswaldo Cruz; 2014 Sep; 109(6):828-33. PubMed ID: 25317712
[TBL] [Abstract][Full Text] [Related]
15. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280
[TBL] [Abstract][Full Text] [Related]
16. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.
Liu Z; Ulrich vonBargen R; Kendricks AL; Wheeler K; Leão AC; Sankaranarayanan K; Dean DA; Kane SS; Hossain E; Pollet J; Bottazzi ME; Hotez PJ; Jones KM; McCall LI
Nat Commun; 2023 Oct; 14(1):6769. PubMed ID: 37880260
[TBL] [Abstract][Full Text] [Related]
17. Profile of Trypanosoma cruzi infection in a tropical medicine reference center, Northern Italy.
Gobbi F; Angheben A; Anselmi M; Postiglione C; Repetto E; Buonfrate D; Marocco S; Tais S; Chiampan A; Mainardi P; Bisoffi Z
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3361. PubMed ID: 25502927
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy and combination chemotherapy for Chagas disease treatment: a systematic review of clinical efficacy and safety based on randomized controlled trials.
Santana Nogueira S; Cardoso Santos E; Oliveira Silva R; Vilela Gonçalves R; Lima GDA; Dias Novaes R
Parasitology; 2022 Nov; 149(13):1679-1694. PubMed ID: 35957576
[TBL] [Abstract][Full Text] [Related]
19. Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment.
Jackson Y; Chatelain E; Mauris A; Holst M; Miao Q; Chappuis F; Ndao M
BMC Infect Dis; 2013 Feb; 13():85. PubMed ID: 23406191
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment.
Mazzeti AL; Gonçalves KR; Mota SLA; Pereira DE; Diniz LF; Bahia MT
Parasitology; 2021 Sep; 148(11):1320-1327. PubMed ID: 34247670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
